Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 7—July 2025
Research
Epidemiologic and Genomic Investigation of Sexually Transmitted Shigella sonnei, England
Hannah Charles
, David R. Greig, Craig Swift, Israel Olonade, Ian Simms, Katy Sinka, Kate S. Baker, Gauri Godbole, and Claire Jenkins
, David R. Greig, Craig Swift, Israel Olonade, Ian Simms, Katy Sinka, Kate S. Baker, Gauri Godbole, and Claire Jenkins
Table 2
Antimicrobial resistance profile of sexually transmitted cases of Shigella sonnei from an epidemiological and genomic investigation of cases within the t10.1814 cluster, England, 2016–2023*
| Antimicrobial and resistance determinant |
Cases, N = 124 |
| Third-generation cephalosporin | |
| blaCTX-M-15 gene variant | 112 (90) |
| blaCTX-M-27 gene variant |
2 (2) |
| Ciprofloxacin: gyrA, parC, or qnr |
116† (94) |
| Azithromycin: ermB or mphA |
109 (88) |
| Extensively drug resistant | 109 (88) |
*Values are no. (%). †All isolates had 2 point mutations in gyrA and 1 point mutation in parC.
Page created: June 17, 2025
Page updated: June 17, 2025
Page reviewed: June 17, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.